Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gwénael Ferron

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Gynecologic Oncology|May 14, 2015
The impact of pleural disease on the management of advanced ovarian cancerCecilia Escayola, Gwénael Ferron, Marga Romeo, et al.
Surgical Oncology|March 2, 2010
Peritoneal pseudomyxoma arising from the urachusAlejandra Martínez, Gwénael Ferron, Eliane Mery, et al.
Gynecologic Oncology|July 1, 2015
Vaginal reconstruction with pedicled vertical deep inferior epigastric perforator flap (diep) after pelvic exenteration. A consecutive case seriesGwénael Ferron, Dimitri Gangloff, Denis Querleu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 27, 2020
CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA TrialBenoit You, Patrick Robelin, Michel Tod, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Gynecologic Oncology|May 14, 2015
The impact of pleural disease on the management of advanced ovarian cancerCecilia Escayola, Gwénael Ferron, Marga Romeo, et al.
Surgical Oncology|March 2, 2010
Peritoneal pseudomyxoma arising from the urachusAlejandra Martínez, Gwénael Ferron, Eliane Mery, et al.
Gynecologic Oncology|July 1, 2015
Vaginal reconstruction with pedicled vertical deep inferior epigastric perforator flap (diep) after pelvic exenteration. A consecutive case seriesGwénael Ferron, Dimitri Gangloff, Denis Querleu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 27, 2020
CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA TrialBenoit You, Patrick Robelin, Michel Tod, et al.
Pageof 1